II. Risk Factors
- See Asthma-Related Death Risk Factors
- Acute
- Viral Upper Respiratory Infections (most common exacerbation trigger)
- Chronic
- Poor symptom control
- Asthma Exacerbation in the last year
- Poor Medication Compliance
- Incorrect use of asthma Inhaler
- Smoking
- Chronic Sinusitis
- Gastroesophageal Reflux
III. Definitions
- Asthma Exacerbation
- Deterioration in baseline symptoms (e.g. Dyspnea, chest tightness, cough, Wheezing) OR
- Deterioration in objective markers (e.g. Pulmonary Function Tests, Oxygen Saturation)
IV. Classification: Asthma Exacerbation Severity
- See Asthma Exacerbation Severity Evaluation
- See SMART Asthma Management Protocol
- Mild Asthma Exacerbation
- Dyspnea on exertion (or Tachypnea in young children)
- Peak Expiratory Flow (PEF) >70% of predicted
- Home management
- Prompt relief with inhaled Short-acting Beta Agonists
- Moderate Asthma Exacerbation
- Dyspnea limits usual activity and patient may speak in phrases
- Peak Expiratory Flow (PEF) 40-69% of predicted
- Tachypnea may be present, but no accessory Muscle use
- Oxygen Saturation 90 to 95%
- Mild Tachycardia (100 to 120 bpm) may be present
- Relief with frequent inhaled Short-acting Beta Agonists
- Office management
- Add oral Systemic Corticosteroids
- Anticipate 1-2 days of symptoms after treatment onset
- Severe Asthma Exacerbation
- Dyspnea at rest, limiting conversation
- Patient may sit forward (e.g. tripoding)
- Tachypnea (>30 breaths/min), Tachycardia (pulse>120 bpm) or Hypoxia (O2 Sat <90%) may be present
- Peak Expiratory Flow (PEF) <40% of predicted
- Only partial relief with inhaled Short-acting Beta Agonists
- Emergency department management
- Hospitalization is likely
- Add Systemic Corticosteroids and ipratroprium
- Anticipte >3 days of some symptoms
- Life Threatening Asthma Exacerbation
- Unable to speak, severe Dyspnea, with associated diaphoresis
- Patient may be confused and with quiet chest, and inappropriately decreased work of breathing (Peri-Arrest)
- Peak Expiratory Flow (PEF) <25% of predicted
- Minimal relief with inhaled Short-acting Beta Agonists
- Emergency department stabilization
- Intensive Care unit admission
- Frequent or continuous Albuterol Nebs
- Add Systemic Corticosteroids and ipratroprium
- ABC Management
V. Management: General
VI. Management: Office-Based Management
- See Emergency Management of Asthma Exacerbation
- Indications
- Mild to moderate Asthma Exacerbation in age >= 6 years
- Contraindications: Need for emergency department management (arrange urgent transfer, while performing stablization below)
- Severe or life threatening Asthma Exacerbation
- Oxygen Saturation <90%
- Failed acute office-based management as below
- Protocol: Acute Office Management
- Albuterol MDI with spacer for 4 to 10 puffs, repeated every 20 minutes as needed for up to 1 hour
- Consider adding Ipratropium Bromide (e.g. duonebs) in moderate exacerbations
- Supplemental Oxygen if Oxygen Saturation <90% (target Oxygen Saturation >93 to 94%)
- Systemic Corticosteroid (e.g. Prednisolone, Prednisone) 1-2 mg/kg up to 40-50 mg orally
- Response will be delayed >6 hours
- Albuterol MDI with spacer for 4 to 10 puffs, repeated every 20 minutes as needed for up to 1 hour
- Disposition (based on 1 hour assessment)
- Worsening or refractory status, or Hypoxia
- Transfer to emergency department
- Discharge to home indications
- Symptoms improving without the need for further Albuterol
- Oxygen Saturation >93 to 94%
- Peak Expiratory Flow >60 to 80% of predicted or personal best
- Adequate resources at home to continue Asthma Exacerbation management
- Worsening or refractory status, or Hypoxia
- Outpatient Management
- Continue short-acting Bronchodilator as needed (or advance SMART Asthma Management Protocol)
- Assess for proper Inhaler use with spacer
- Review Asthma Action Plan
- Start or step-up controller medication
- Continue oral Corticosteroids for 3 to 5 days in children (5 to 7 days in adults)
- Follow-up at 1 to 2 days in children (2 to 7 days in adults)
- Assess for exacerbation improvement
- Consider extension of Systemic Corticosteroids if significant persistent, refractory symptoms
- Consider short-term (1 to 2 weeks) or long-term (3 months) advancement of controller medications
- Taper short-acting Bronchodilator as able (or SMART Asthma Management Protocol)
- Review Asthma Action Plan (consider modifications and emphasize compliance)
- Refer to Asthma and allergy specialist for >1 to 2 exacerbations per year
VII. Prevention
- See Asthma-Related Death Risk Factors
- Manage chronic modifiable predisposing conditions
- School-based Asthma intervention programs
VIII. References
- (2022) Global Strategy for Asthma Management and Prevention (GINA)
- (2007) Guidelines for the diagnosis and management of Asthma, NHLBI
- Dabbs (2024) Am Fam Physician 109(1): 43-50 [PubMed]